NCT06026787View on ClinicalTrials.gov

Clinical Value of Adding Dapagliflozin in Patients With Nephrotic Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

August 1, 2023

Study Completion Date

August 1, 2023

Conditions
Nephrotic SyndromeSodium-Glucose Transporter 2 Inhibitors
Interventions
DRUG

Dapagliflozin 10mg Tab

Dapagliflozin 10 mg will be added to the standard of care regimen of primary nephrotic syndrome patients

Trial Locations (1)

Unknown

Ain Shams University Hospitals, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER